- Craig-Hallum analyst Jason Kreyer lowered the price target on Cardlytics Inc CDLX to $100 from $120, implying a 25.4% upside, and reiterated a Buy.
- While broader macro concerns over supply chain issues and corresponding labor shortages have been widely topical over the past month, Cardlytics cited these headwinds a quarter ago, reset expectations, and is now working through this new paradigm, the analyst contends.
- Kreyer notes that results for the quarter were "solid," and while the Q4 guide is "mildly underwhelming," he believes it encompasses a more conservative guide given impending concerns over what macro factors may impose on the holiday shopping season.
- The advertising platform reported third-quarter FY21 revenue growth of 41% year-on-year to $65 million, beating the consensus of $62.1 million.
- Billings grew 59% Y/Y to $98.4 million, Cardlytics MAUs were 170.6 million, up 6% Y/Y, and Cardlytics ARPU was $0.36, up 24% Y/Y.
- Non-GAAP EPS loss of $(0.33) beat the consensus loss of $(0.54).
- Cardlytics sees Q4 revenue of $70 million - $80 million and FY21 revenue of $247.1 million - $257.1 million.
- Cardlytics sees Q4 billings of $105 million - $120 million and FY21 billings of $365.1 million - $380.1 million.
- Price Action: CDLX shares closed higher by 11.05% at $88.54 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in